Review Article
Research progress of CD13-targeted molecular probe in tumor neovascularization imaging and therapy
Wu Minghao, Zhang Yanyan, Cao Lin, Zhang Xuening, Ye Zhaoxiang
Published 2019-11-25
Cite as Chin J Nucl Med Mol Imaging, 2019, 39(11): 688-693. DOI: 10.3760/cma.j.issn.2095-2848.2019.11.013
Abstract
Tumor neovascularization plays an important role in the occurrence, development and metastasis of cancer. Non-invasive quantification and detection of tumor neovascularization is crucial for early diagnosis and prognosis assessment of cancer. Targeted molecular imaging has arisen in vascular targeting imaging and precise treatment based on the molecular characteristics of neovascularization. Aminopeptidase N (APN, or CD13) is a multifunctional membrane-bound exopeptidase that is overexpressed in neovascular endothelial cells and some tumor cells but rarely expressed in normal blood vessels, which makes it a potential target for tumor neovascularization imaging and anti-angiogenic therapy. This review summarizes the application progress and the future development trend of target molecular imaging and precise treatment based on CD13.
Key words:
Neoplasms; Neovascularization, pathologic; Angiogenesis inhibitors; Antigens, CD13; Trends
Contributor Information
Wu Minghao
Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin and Tianjin′s Clinical Research Center for Cancer, Tianjin 300060, China
Zhang Yanyan
Cao Lin
Zhang Xuening
Ye Zhaoxiang